Business & Finance
Innovus Pharma's Partner Lavasta Receives Approval from Algeria to Market and Sell Zestra and Zestra Glide in that Country
16 May 2019 - - US-based specialty pharmaceutical company Innovus Pharmaceuticals, Inc.'s (OTCQB Venture Market: INNV) partner, Dubai-based Lavasta Pharma RFZ-LLC, has received approval from the Algerian Ministry of Health and Commerce to market and sell Innovus' Zestra and Zestra Glide products in that country, the company said.

In addition, Innovus Pharma announced that it received a purchase order from Lavasta Pharma for these two products for approximately USD 186,000.

Innovus signed an exclusive distribution agreement with Lavasta to market and sell Zestra, Zestra Glide and ProstaGorx for prostate health in 2018.

Besides Algeria, Lavasta has rights to market and sell Zestra and Zestra Glide upon regulatory approval in over thirty countries in the Middle East, North Africa and West Africa.

Besides, Lavasta, Zestra is currently exclusively partnered with Orimed Pharma, the OTC subsidiary of Jamp Pharma, in Canada, Densmore in France and Belgium, DanaLife ApS in select European markets and Li USA, Co. for South Korea, and non-exclusively to PT Resources in Hong Kong and certain select Asian markets.

Zestra is currently approved to be commercialized in 38 countries in the world namely, in Canada, the 28 countries of the European Union, Australia, New Zealand, India, Hong Kong, the United Arab Emirates, South Korea, Morocco, Algeria and Malaysia.

Innovus Pharma currently generates revenues from the following markets for Zestra: Canada, Australia, Morocco, Malaysia, certain European countries, South Korea and Hong Kong in addition to the United States as its biggest market.

Zestra is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistically significant manner the arousal, desire and sexual satisfaction in women with Female Sexual Interest/Arousal Disorder.

To the company's knowledge, Zestra is the first NHP product to receive approval for the indication of FSI/AD in Canada.

To date, no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity.

The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress.

Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger.

Approximately 43% of women in the United States age 18 to 59, or ~50 m, experience some form of Female Sexual Dysfunction according to a published study. (Laumann, E.O. et al. Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA, Feb. 10, 1999. vol. 281, No. 6.537-542). The FSD market in the United States is estimated to be more than USD 1bn per year.

Zestra Glide is a clinically tested water-based longer lasting lubricant. In a 57 patient safety clinical study, Zestra Glide proved to be safe and caused no irritation or skin side effects during the six week trial.